MENCORE-2: Audio Recordings to Improve Decision-making in Advanced Prostate Cancer

PRIMARY OBJECTIVE:

• To evaluate change in participant informed decision-making after provision of a consultation audio recording application.

SECONDARY OBJECTIVES:

• Reach. To evaluate the percentage of invited participants who enroll. Reasons for not enrolling will be assessed.
• Adoption. To evaluate the percentage of providers who agree to be recorded.
• Adoption. To evaluate the percentage of participants who create an audio recording.
• Adoption. To evaluate the percentage of participants who listen to the audio recording or read its automatically generated transcript.
• Implementation. To evaluate the percentage of participants who report receiving instructions on how to record.
• To evaluate participant-reported shared decision-making effort.
• To evaluate whether participant-reported anxiety changes after provision of a consultation audio recording app.
• To evaluate barriers, facilitators, and experiences of recording app use, particularly in the context of treatment decision-making by conducting participant interviews, provider surveys, and interviews with providers.
• Treatment received.

EXPLORATORY OBJECTIVES:

• To evaluate whether provision of a consultation audio recording app improves participant-reported knowledge retention of docetaxel.
• To evaluate accuracy of app auto-generated transcription.
• To evaluate degree of provider decision support and communication skills.

Participants are set up with an application prior to the first physician visit and then followed-up 7 days, 28 days and 60 days after their physician encounter.

Inclusion criteria

• Metastatic castration-resistant prostate cancer (mCRPC) with progression per any Prostate Cancer Working Group 3 (PCWG3) criterion (Prostate-specific antigen (PSA), clinical, or radiographic)
• Has never received any chemotherapy for prostate cancer.
• Current or prior receipt of at least one androgen-signaling inhibitors (ASI) (abiraterone, enzalutamide, apalutamide, or darolutamide), with progression on it.
• Eligible for docetaxel chemotherapy at any dose level (treating provider's discretion).
• Has an upcoming genitourinary (GU) medical oncology appointment (in-person, telephone, or Zoom video visit) at University of California, San Francisco (UCSF) within 7-60 days of enrollment, during which next-line treatment options are anticipated to be discussed (treating provider's discretion).
• 18 years of age or older.
• Able to read, speak, and write in English (the application is in English only)
• Has access to and ability to use an iOS or Android smartphone or tablet.
• For video visits only: has access to and ability to use a second device (e.g., desktop, laptop, smartphone, tablet, etc.) that will run a Zoom video visit.
• Patient's provider of the upcoming appointment in #5 agrees to be recorded.

Inclusion criteria

(provider participants):

• UCSF GU medical oncology providers (medical doctor (MD), nurse practitioner (NP), or physician's assistant (PA)), regardless of whether their patient was enrolled

Exclusion criteria

• Lack of decision-making capacity to provide consent to this trial.
• Uncorrectable hearing or visual impairment hindering the ability to perform necessary tasks in the trial.
• Any neurocognitive or psychiatric disorder hindering the ability to perform necessary tasks in the trial.
• Prior participation in Mobile Health ElectroNic COnsultation REcording (mENCORE) (participants have already received the intervention).